The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05692596
• Other study ID #: MCC-22156
• Status: Recruiting
• Start date: October 6, 2022
• Est. completion date: August 2025

Study information

• Verified date: January 2024
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: August 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)

• Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.

• Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Related Conditions & MeSH terms

• Ataxia Telangiectasia
• BRCA Mutation
• Chronic Pancreatitis
• Colorectal Neoplasms, Hereditary Nonpolyposis
• Dysplastic Nevus Syndrome
• FAP
• Lynch Syndrome
• PALB2 Gene Mutation
• Pancreatic Cyst
• Pancreatic Ductal Adenocarcinoma
• Pancreatitis
• Pancreatitis, Chronic
• Peutz-Jeghers Syndrome
• Syndrome
• Telangiectasis

Intervention

Other:
• Data collection
Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

Locations

Country	Name	City	State
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Database creation	A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.	24 months

External Links

•   Moffitt Cancer Center Clinical Trials website